Experience with Tofacitinib in Patients with Ulcerative Colitis: Data from a United States Claims Database.

ABSTRACT:

Background

Tofacitinib is an oral small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC).

Aims

To evaluate real-world data in US patients with UC receiving tofacitinib.

Methods

Characteristics and outcomes of patients with UC initiating tofacitinib between 2018 and 2019 were assessed using data from the IBM® MarketScan® claims database. The index date was the first tofacitinib claim; pre- and post-index periods were 12 months. Outcomes included tofacitinib adherence/persistence, oral corticosteroid (OCS) use, and healthcare resource utilization (HCRU) and costs.

Results

Of 276 patients with UC who initiated tofacitinib, 68 (24.6%) were bio-naïve, and 208 (75.4%) bio-experienced. At month 12, overall median tofacitinib adherence (prop

SUBMITTER: Chiorean M 

PROVIDER: S-EPMC10516786 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature